SpringWorks Therapeutics, Inc. - common stock (SWTX)
44.72
-0.21 (-0.47%)
NASDAQ · Last Trade: Apr 27th, 6:58 PM EDT
Detailed Quote
Previous Close
44.93
Open
44.85
Bid
44.69
Ask
44.75
Day's Range
44.19 - 45.01
52 Week Range
28.21 - 62.00
Volume
7,806,554
Market Cap
2.20B
PE Ratio (TTM)
-18.33
EPS (TTM)
-2.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,825,732
Chart
About SpringWorks Therapeutics, Inc. - common stock (SWTX)
Springworks Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for underserved patient populations, particularly in the field of rare diseases and oncology. The company utilizes its proprietary drug development platform to identify and advance novel treatments, focusing on precision medicine approaches. By leveraging its expertise in biomarker-driven strategies, Springworks aims to bring transformative therapeutics to market, addressing significant unmet medical needs and improving the quality of life for patients dealing with complex health challenges. Read More
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025.
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates.
